ethaboxam: a fungicide; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ethaboxam : A racemate comprising equimolar amounts of (R)- and (S)-ethaboxam. A fungicide used to control Oomycetes in vines and late potato blight. It is moderately toxic to birds, most aquatic species, honey bees and earthworms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
N-[cyano(2-thienyl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide : A member of the class of aromatic amides obtained by formal condensation of the carboxy group of 4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxylic acid with the amino group of amino(2-thienyl)acetonitrile. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11174640 |
| CHEBI ID | 82857 |
| SCHEMBL ID | 20484 |
| MeSH ID | M0473730 |
| Synonym |
|---|
| ethaboxam |
| 162650-77-3 |
| 7mp0l17bm8 , |
| unii-7mp0l17bm8 |
| ethaboxam [iso] |
| 5-thiazolecarboxamide, n-(cyano-2-thienylmethyl)-4-ethyl-2-(ethylamino)- |
| SCHEMBL20484 |
| CHEBI:82857 |
| n-[cyano(2-thienyl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide |
| DTXSID2057994 |
| NQRFDNJEBWAUBL-UHFFFAOYSA-N |
| 2-ethylamino-4-ethyl-thiazole-5-carboxylic acid (cyano-thiophen-2-yl-methyl)-amide |
| EX-A888 |
| n-(cyano-2-thienylmethyl)-4-ethyl-2-(ethylamino)-5-thiazolecarboxamide |
| J-009962 |
| FT-0700234 |
| ethofin; guardian; intego solo |
| BCP28799 |
| Q19279350 |
| n-[cyano(thiophen-2-yl)methyl]-4-ethyl-2-(ethylamino)-1,3-thiazole-5-carboxamide |
Ethaboxam is a benzamide antioomycete chemical (oomicide) used in corn and soybean seed treatments.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ethaboxam is a benzamide antioomycete chemical (oomicide) used in corn and soybean seed treatments. " | ( Convergent Evolution of C239S Mutation in Chilvers, MI; Noel, ZA; Roth, MG; Sang, H, 2019) | 1.96 |
| Class | Description |
|---|---|
| aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
| aromatic amine | An amino compound in which the amino group is linked directly to an aromatic system. |
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| 1,3-thiazoles | |
| thiophenes | Compounds containing at least one thiophene ring. |
| nitrile | A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.68) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||